Barclays’s Cumberland Pharmaceuticals CPIX Stock Holding History

Barclays’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$7	–	5523
2025 Q2	$7	Buy	+2	New	+$9	﹤0.01%	5161
2020 Q3	–	Sell	-22	Closed	–	–	5261
2020 Q2	$0	Buy	+22	New	+$80	﹤0.01%	5653
2020 Q1	–	Sell	-3	Closed	–	–	6175
2019 Q4	$0	Sell	3 -82	-96%	-$433	﹤0.01%	6401
2019 Q3	$1K	Buy	+85	New	+$473	﹤0.01%	6579
2013 Q3	–	Sell	-10,761	Closed	-$55K	–	7429
2013 Q2	$55K	Buy	+10,761	New	+$53.5K	﹤0.01%	6243

Other funds holding CPIX

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Barclays's CPIX Position: Q3 2025 in Review

Barclays sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2025, closing a stake of 2 shares — an estimated $7 sold.

Barclays first reported a position in CPIX in Q2 2013 and held it in 5 quarters. The position peaked at $55K in Q2 2013. 30 funds tracked by Wall St. Rank hold CPIX as of Q3 2025.

Barclays reported no remaining Cumberland Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Barclays sold 2 Cumberland Pharmaceuticals shares in Q3 2025, an estimated $7.
Barclays first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Barclays's Cumberland Pharmaceuticals position peaked at $55K in Q2 2013.
30 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.